Silexion Therapeutics Corp — Form 8-K
Filed September 25, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Silexion Therapeutics Corp filed an 8-K on 2026-09-25 disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing provides no specific details on which listing rule was violated, remediation timeline, or financial impact. The company, with ~$4.2M in total assets, has not disclosed concrete counterparties, dollar amounts, or dates beyond the filing date.
Why this rating
Delisting threat is existential for a $4.2M-asset biotech firm; loss of public listing access destroys capital-raising ability and shareholder value.
Extracted items
Tradability signal
NO TRADE
No trade: price $0.01 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.01 ▼ 0.00% | at our read · unknown $0.01 | +10 min · unknown $0.01 ▲ 0.00% | +30 min · unknown $0.01 ▲ 0.00% | +1 hr · unknown $0.01 ▲ 0.00% | +4 hrs · unknown $0.01 ▲ 0.00% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.